| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.20005.14.589 |
| P698 | PubMed publication ID | 16192580 |
| P50 | author | Giuseppe Giaccone | Q37829946 |
| Andrew Bottomley | Q66812411 | ||
| P2093 | author name string | Mark Vincent | |
| Jan P van Meerbeeck | |||
| Christian Manegold | |||
| Eric A Van Marck | |||
| Catherine Legrand | |||
| Channa Debruyne | |||
| National Cancer Institute of Canada | |||
| Rabab Gaafar | |||
| Rob J Van Klaveren | |||
| European Organisation for Research and Treatment of Cancer Lung Cancer Group | |||
| P433 | issue | 28 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| patient | Q181600 | ||
| cisplatin | Q412415 | ||
| malignant pleural mesothelioma | Q18557602 | ||
| P304 | page(s) | 6881-6889 | |
| P577 | publication date | 2005-10-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst | |
| P478 | volume | 23 |
| Q30474771 | A 26-year-old male with mesothelioma due to asbestos exposure |
| Q93369091 | A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma |
| Q37296603 | A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307 |
| Q53003365 | A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma. |
| Q38760623 | A catalogue of treatment and technologies for malignant pleural mesothelioma |
| Q40522944 | A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. |
| Q33414357 | A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma |
| Q33812537 | A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma |
| Q41846143 | A potential therapeutic strategy for malignant mesothelioma with gene medicine |
| Q35190713 | A randomised controlled trial of intravenous zoledronic acid in malignant pleural disease: a proof of principle pilot study |
| Q59132458 | A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205) |
| Q46115026 | Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients |
| Q36948470 | Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma |
| Q36727434 | Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial |
| Q64889484 | Advances in pulmonary and pleural malignant disorders. |
| Q47912434 | Advances in systemic therapy for malignant mesothelioma: future perspectives |
| Q38153818 | Advances in the management of pleural disease. |
| Q37070229 | Advances in the systemic therapy of malignant pleural mesothelioma |
| Q38800916 | Advances in treatment of mesothelioma. |
| Q33813008 | An epigenetic mechanism for capecitabine resistance in mesothelioma |
| Q52659191 | An innovative mesothelioma treatment based on miR-16 mimic loaded EGFR targeted minicells (TargomiRs). |
| Q35182037 | Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). |
| Q51757551 | Analysis of the effect of radiotherapy on malignant pleural mesothelioma when given on adjuvant or palliative basis |
| Q90056612 | Antiangiogeneic Strategies in Mesothelioma |
| Q33530405 | Antimetabolites and cancer: emerging data with a focus on antifolates |
| Q50864512 | Antimetabolites in the treatment of advanced pleural mesothelioma: a network meta-analysis of randomized clinical trials. |
| Q51428846 | Asbestos and the lung in the 21st century: an update. |
| Q28533736 | BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma |
| Q27851697 | BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. |
| Q30478994 | BTS statement on malignant mesothelioma in the UK, 2007. |
| Q37335377 | Biomarkers for malignant pleural mesothelioma: current status |
| Q55053946 | Biomarkers in malignant mesothelioma-an unfulfilled need or a waste of resources? |
| Q52579899 | CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. |
| Q88682206 | Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study |
| Q38119922 | Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. |
| Q64235291 | Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP) |
| Q35141369 | Chemotherapy and targeted therapies for unresectable malignant mesothelioma |
| Q81295701 | Chemotherapy for malignant pleural mesothelioma |
| Q83789589 | Chemotherapy for malignant pleural mesothelioma |
| Q37090808 | Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future |
| Q52672893 | Chemotherapy treatment in malignant pleural mesothelioma: a difficult history. |
| Q36755228 | Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma |
| Q34957369 | Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma |
| Q50050310 | Clinical and biologic prognostic factors in malignant pleural mesothelioma |
| Q35542880 | Clinical characteristics and treatment outcomes in 132 patients with malignant mesothelioma |
| Q37679984 | Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma |
| Q59137556 | Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations |
| Q59132464 | Current chemotherapy strategies in malignant pleural mesothelioma |
| Q37086026 | Current concepts in malignant pleural mesothelioma. |
| Q28393560 | Current issues in malignant pleural mesothelioma evaluation and management |
| Q37232309 | Current therapies for malignant pleural mesothelioma |
| Q38059514 | Dendritic cell-based immunotherapy in mesothelioma |
| Q37612152 | Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. |
| Q47974790 | Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation? : A planning study |
| Q53214981 | Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. |
| Q90748160 | Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading? |
| Q36758593 | Emerging drugs for mesothelioma |
| Q48060347 | Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care |
| Q34035015 | Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data |
| Q39298123 | Expression of Wilms' tumor gene (WT1) is associated with survival in malignant pleural mesothelioma. |
| Q39933225 | Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: association with cyclooxygenase-2 and prognosis |
| Q89017219 | FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients |
| Q51617036 | FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival. |
| Q33639709 | First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers |
| Q35832320 | First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. |
| Q89598585 | Formulation of Folate-Modified Raltitrexed-Loaded Nanoparticles for Colorectal Cancer Theranostics |
| Q36354734 | From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q37243005 | Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810) |
| Q40176023 | Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. |
| Q28394028 | Guidelines for the diagnosis and treatment of malignant pleural mesothelioma |
| Q48394328 | Health-related quality of life and inflammatory markers in malignant pleural mesothelioma |
| Q37810109 | Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes |
| Q37662700 | Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials |
| Q36259724 | Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. |
| Q35642044 | Immune microenvironments in solid tumors: new targets for therapy |
| Q84596250 | Impact of tumor angiogenesis in peritoneal mesothelioma after radical cytoreduction and hyperthermic intraperitoneal chemotherapy |
| Q33877584 | Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma. |
| Q36322368 | Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients |
| Q37880216 | Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation |
| Q39769492 | Incidence of interstitial lung disease in patients with mesothelioma in the west part of Japan |
| Q39818881 | Individualizing Mesothelioma Treatment: Small Steps Into a Brighter Future |
| Q39350596 | Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma |
| Q34293068 | Investigational approaches for mesothelioma |
| Q91123540 | Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial |
| Q38633115 | Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma |
| Q28395597 | Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies |
| Q37666267 | Lung Cancer OncoGuia |
| Q31019143 | MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data |
| Q34182679 | MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma |
| Q39366003 | Malignant Mesothelioma: Time to Translate? |
| Q35623638 | Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy. |
| Q21202901 | Malignant mesothelioma |
| Q47098675 | Malignant mesothelioma: Canadian perspective and research directions |
| Q33909330 | Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis |
| Q83412919 | Malignant pleural mesothelioma |
| Q59274199 | Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q34513958 | Malignant pleural mesothelioma: an update on diagnosis and treatment options |
| Q37217764 | Malignant pleural mesothelioma: current and future perspectives |
| Q37529848 | Malignant pleural mesothelioma: current treatments and emerging drugs. |
| Q26821919 | Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health |
| Q36728254 | Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies. |
| Q37866786 | Malignant pleural mesothelioma: when is radiation therapy indicated? |
| Q37277434 | Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG). |
| Q35834928 | Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study). |
| Q36830116 | Management options for malignant pleural mesothelioma: clinical and cost considerations |
| Q33705743 | Measuring symptoms as a critical component of drug development and evaluation in hematological diseases |
| Q38542421 | Medical and oncological management of malignant mesothelioma. |
| Q37866663 | Medical treatment of mesothelioma: anything new? |
| Q38476131 | Mesothelioma treatment |
| Q26800042 | Mesothelioma treatment: Are we on target? A review |
| Q58416980 | Metabolic vulnerability of cisplatin-resistant cancers |
| Q37956213 | Metastases to the oral region from pleural mesothelioma: Clinicopathologic review. |
| Q44669659 | Methodological issues in designing and reporting health-related quality of life in cancer clinical trials: the challenge of brain cancer studies |
| Q29248127 | Modern management of malignant pleural mesothelioma |
| Q36699347 | Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability |
| Q37232301 | Molecular biology of malignant mesothelioma |
| Q33372250 | Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease). |
| Q52581757 | New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma. |
| Q87296127 | New directions in the second line treatment of non-small cell lung cancers and in the management of malignant pleural mesotheliomas |
| Q34101029 | New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells. |
| Q26859274 | New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas |
| Q36780582 | Newer issues in mesothelioma chemotherapy. |
| Q92134619 | Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial |
| Q99582736 | Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program |
| Q39455555 | Novel insights into mesothelioma biology and implications for therapy. |
| Q33890499 | Novel systemic therapy against malignant pleural mesothelioma |
| Q52672324 | Novel therapies for malignant pleural mesothelioma. |
| Q38662242 | Optimal Therapy of Advanced Stage Mesothelioma |
| Q50484415 | Optimal gross tumor volume definition in lung-sparing intensity modulated radiotherapy for pleural mesothelioma: an in silico study. |
| Q36905239 | Optimising survival in malignant mesothelioma |
| Q34360248 | Overview of the biochemical and genetic processes in malignant mesothelioma. |
| Q37252398 | PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma |
| Q38398970 | PTEN protein expression in malignant pleural mesothelioma |
| Q34516941 | Pemetrexed in thoracic cancer |
| Q33379936 | Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. |
| Q37081896 | Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma |
| Q40166240 | Pleural Diseases: Saline Irrigation in Pleural Infection, Epidemiology of Pneumothorax, and Bevacizumab in Mesothelioma |
| Q28487719 | Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma |
| Q50049398 | Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma |
| Q38961442 | Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma |
| Q43875251 | Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma |
| Q53175010 | Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma. |
| Q55318621 | Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma. |
| Q37945636 | Raltitrexed in mesothelioma |
| Q64250473 | Raltitrexed increases radiation sensitivity of esophageal squamous carcinoma cells |
| Q36425940 | Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma |
| Q34142500 | Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma |
| Q34402081 | Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. |
| Q58128741 | Review of nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial |
| Q38190418 | Role of microRNAs in malignant mesothelioma. |
| Q50665635 | Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study. |
| Q26860736 | Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis |
| Q37582256 | Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review |
| Q54957187 | Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma. |
| Q37862752 | Soluble markers for diagnosis of malignant pleural mesothelioma |
| Q34096881 | Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels |
| Q44080402 | Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis |
| Q36594263 | Surgical controversies in mesothelioma: MesoVATS addresses the role of surgical debulking |
| Q51716124 | Surgical resection of mesothelioma: an evidence-free practice. |
| Q38607308 | Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response |
| Q41279899 | Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists |
| Q93380858 | Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma |
| Q37992694 | Systemic treatment of malignant pleural mesothelioma |
| Q37260408 | Systemic treatments for mesothelioma: standard and novel |
| Q52672891 | Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma. |
| Q55247848 | Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications. |
| Q38704895 | Targeting YAP in malignant pleural mesothelioma. |
| Q47107902 | Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models |
| Q43800002 | Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study |
| Q47133389 | The "don't eat me" signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma |
| Q89502927 | The Role of Neoadjuvant Chemotherapy in Patients with Resectable Malignant Pleural Mesothelioma - An Institutional and National Analysis |
| Q35686558 | The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma |
| Q38148036 | The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms |
| Q35200628 | The role of interleukin-6 in malignant mesothelioma |
| Q59132459 | The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey |
| Q36980982 | Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: physical functioning, emotional functioning, fatigue and pain |
| Q37745215 | Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia. |
| Q37806309 | Translational advances in pleural malignancies |
| Q37734455 | Translational therapies for malignant pleural mesothelioma. |
| Q61583558 | Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future |
| Q38631254 | Tremelimumab for the treatment of malignant mesothelioma |
| Q90808642 | Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial |
| Q50612432 | Unusual Contiguous Soft Tissue Spread of Advanced Malignant Mesothelioma Detected by FDG PET/CT. |
| Q45226201 | Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. |
| Q38602994 | Use of the lung cancer-specific Quality of Life Questionnaire EORTC QLQ-LC13 in clinical trials: A systematic review of the literature 20 years after its development |
| Q38758684 | Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials |
| Q36946792 | Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. |
| Q39947427 | YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation |
| Q84192226 | [Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion] |
| Q82061962 | [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma] |
| Q80426618 | [Malignant pleural mesothelioma: interrogations and hopes concerning the expected epidemic] |
| Q81415520 | [Role of DNA microarrays in the diagnosis of pleural exudates: a feasibility study] |
Search more.